journal
MENU ▼
Read by QxMD icon Read
search

Lancet Haematology

journal
https://www.readbyqxmd.com/read/29752199/gemcitabine-oxaliplatin-plus-rituximab-r-gemox-as-first-line-treatment-in-elderly-patients-with-diffuse-large-b-cell-lymphoma-a-single-arm-open-label-phase-2-trial
#1
Qiu-Dan Shen, Hua-Yuan Zhu, Li Wang, Lei Fan, Jin-Hua Liang, Lei Cao, Wei Wu, Yi Xia, Jian-Yong Li, Wei Xu
BACKGROUND: The combination of rituximab, gemcitabine, and oxaliplatin (R-GemOx) has shown high efficacy with a low toxicity profile in elderly patients with relapsed and refractory diffuse large B-cell lymphoma. We aimed to evaluate the efficacy, safety, and feasibility of the R-GemOx regimen as a first-line treatment in elderly patients with diffuse large B-cell lymphoma. METHODS: In this single-arm, open-label, phase 2 clinical trial, we enrolled patients with previously untreated, histologically confirmed, CD20-positive diffuse large B-cell lymphoma, aged 70 years or older, or aged 60-69 years with an Eastern Cooperative Oncology Group (ECOG) performance status score of 2 or greater...
May 8, 2018: Lancet Haematology
https://www.readbyqxmd.com/read/29731369/tailored-frequency-escalated-primary-prophylaxis-for-severe-haemophilia-a-results-of-the-16-year-canadian-hemophilia-prophylaxis-study-longitudinal-cohort
#2
Brian M Feldman, Georges E Rivard, Paul Babyn, John K M Wu, MacGregor Steele, Man-Chiu Poon, Robert T Card, Sara J Israels, Nicole Laferriere, Kulwant Gill, Anthony K Chan, Manuel Carcao, Robert J Klaassen, Stephanie Cloutier, Victoria E Price, Saunya Dover, Victor S Blanchette
BACKGROUND: Severe haemophilia A has high morbidity, and treatment, while effective, is very expensive. We report the 16-year follow-up of the Canadian Hemophilia Prophylaxis Study, which examined the effectiveness of tailored frequency-escalated primary prophylaxis with a focus on health outcomes within the domains of body structures and functions, and activities and participation (according to the WHO International Classification of Functioning, Disability and Health [WHO-ICF] framework) and a view to reducing consumption of costly clotting factor, which accounts for more than 90% of the cost of care of severe haemophilia...
May 3, 2018: Lancet Haematology
https://www.readbyqxmd.com/read/29650494/does-q-fever-contribute-to-pathogenesis-of-non-hodgkin-lymphoma
#3
Kevin A David, Athena Kritharis, Andrew M Evens
No abstract text is available yet for this article.
April 9, 2018: Lancet Haematology
https://www.readbyqxmd.com/read/29650493/exposure-to-coxiella-burnetii-and-risk-of-non-hodgkin-lymphoma-a-retrospective-population-based-analysis-in-the-netherlands
#4
Sonja E van Roeden, Fedor van Houwelingen, Chiel M J Donkers, Sander J Hogewoning, Marit M A de Lange, Wim van der Hoek, Linda M Kampschreur, Marc J M Bonten, Andy I M Hoepelman, Chantal P Bleeker-Rovers, Peter C Wever, Jan Jelrik Oosterheert
BACKGROUND: An association between Coxiella burnetii and non-Hodgkin lymphoma has been suggested. After a large Q fever epidemic in the Netherlands (2007-10), we postulated that the incidence of non-Hodgkin lymphoma would be increased during and after the epidemic in areas with a high endemicity of Q fever compared with those with low endemicity. METHODS: We did a retrospective population-based analysis and calculated relative risks (RRs) of non-Hodgkin lymphoma during 1-year periods before, during, and after the Q fever epidemic, for areas with intermediate and high endemicity of Q fever compared with low endemic areas...
April 9, 2018: Lancet Haematology
https://www.readbyqxmd.com/read/29628398/defining-clinically-relevant-measures-of-iron-overload-around-haemopoietic-stem-cell-transplantation
#5
Heather A Leitch
No abstract text is available yet for this article.
April 5, 2018: Lancet Haematology
https://www.readbyqxmd.com/read/29628397/enhanced-labile-plasma-iron-and-outcome-in-acute-myeloid-leukaemia-and-myelodysplastic-syndrome-after-allogeneic-haemopoietic-cell-transplantation-allive-a-prospective-multicentre-observational-trial
#6
Martin Wermke, Julia Eckoldt, Katharina S Götze, Stefan A Klein, Gesine Bug, Liesbeth C de Wreede, Michael Kramer, Friedrich Stölzel, Malte von Bonin, Johannes Schetelig, Michael Laniado, Verena Plodeck, Wolf-Karsten Hofmann, Gerhard Ehninger, Martin Bornhäuser, Dominik Wolf, Igor Theurl, Uwe Platzbecker
BACKGROUND: The effect of systemic iron overload on outcomes after allogeneic haemopoietic cell transplantation (HCT) has been a matter of substantial debate. We aimed to investigate the predictive value of both stored (MRI-derived liver iron content) and biologically active iron (enhanced labile plasma iron; eLPI) on post-transplantation outcomes in patients with acute myeloid leukaemia or myelodysplastic syndrome undergoing allogenic HCT. METHODS: The prospective, multicentre, observational, ALLogeneic Iron inVEstigators (ALLIVE) trial recruited patients at five centres in Germany...
April 5, 2018: Lancet Haematology
https://www.readbyqxmd.com/read/29550384/long-term-efficacy-of-reduced-intensity-versus-myeloablative-conditioning-before-allogeneic-haemopoietic-cell-transplantation-in-patients-with-acute-myeloid-leukaemia-in-first-complete-remission-retrospective-follow-up-of-an-open-label-randomised-phase-3-trial
#7
Frederick Fasslrinner, Johannes Schetelig, Andreas Burchert, Michael Kramer, Rudolf Trenschel, Ute Hegenbart, Michael Stadler, Kerstin Schäfer-Eckart, Michael Bätzel, Hans Eich, Martin Stuschke, Rita Engenhart-Cabillic, Mechthild Krause, Peter Dreger, Andreas Neubauer, Gerhard Ehninger, Dietrich Beelen, Wolfgang E Berdel, Timo Siepmann, Matthias Stelljes, Martin Bornhäuser
BACKGROUND: The impact of the intensity of conditioning before allogeneic haemopoietic cell transplantation (HCT) has been studied in a randomised phase 3 trial comparing reduced-intensity conditioning with myeloablative conditioning in patients with acute myeloid leukaemia in first complete remission. Because of the short follow-up of the original trial, whether reduced-intensity conditioning increases the risk of late relapse compared with myeloablative conditioning remained unclear...
March 14, 2018: Lancet Haematology
https://www.readbyqxmd.com/read/29550382/voxtalisib-xl765-in-patients-with-relapsed-or-refractory-non-hodgkin-lymphoma-or-chronic-lymphocytic-leukaemia-an-open-label-phase-2-trial
#8
Jennifer R Brown, Mehdi Hamadani, John Hayslip, Ann Janssens, Nina Wagner-Johnston, Oliver Ottmann, Jon Arnason, Hervé Tilly, Michael Millenson, Fritz Offner, Nashat Y Gabrail, Siddhartha Ganguly, Sikander Ailawadh, Siddha Kasar, Arnon P Kater, Jeanette K Doorduijn, Lei Gao, Joanne J Lager, Bin Wu, Coumaran Egile, Marie José Kersten
BACKGROUND: Patients with relapsed or refractory lymphoma or chronic lymphocytic leukaemia have a poor prognosis. Therapies targeting more than one isoform of PI3K, as well as mTOR, might increase antitumour activity. We aimed to investigate the efficacy and safety of voxtalisib (also known as XL765 or SAR245409), a pan-PI3K/mTOR inhibitor, in patients with relapsed or refractory lymphoma, or chronic lymphocytic leukaemia/small lymphocytic lymphoma. METHODS: We did a non-randomised, open-label, phase 2 trial at 30 oncology clinics in the USA, Belgium, Germany, France, the Netherlands, and Australia...
March 14, 2018: Lancet Haematology
https://www.readbyqxmd.com/read/29550381/conditioning-intensity-in-hct-for-aml-the-jury-is-still-out
#9
Charles Craddock
No abstract text is available yet for this article.
March 14, 2018: Lancet Haematology
https://www.readbyqxmd.com/read/29550380/clinical-development-of-voxtalisib-a-pan-pi3k-mtor-inhibitor
#10
Wataru Munakata, Kensei Tobinai
No abstract text is available yet for this article.
March 14, 2018: Lancet Haematology
https://www.readbyqxmd.com/read/29548624/sickle-cell-anaemia-needs-more-food
#11
Hyacinth I Hyacinth
No abstract text is available yet for this article.
March 13, 2018: Lancet Haematology
https://www.readbyqxmd.com/read/29548623/ready-to-use-food-supplement-with-or-without-arginine-and-citrulline-with-daily-chloroquine-in-tanzanian-children-with-sickle-cell-disease-a-double-blind-random-order-crossover-trial
#12
Sharon E Cox, Elizabeth A Ellins, Alphonce I Marealle, Charles R Newton, Deogratias Soka, Philip Sasi, Gian Luca Di Tanna, William Johnson, Julie Makani, Andrew M Prentice, Julian P Halcox, Fenella J Kirkham
BACKGROUND: Sickle-cell disease increases the risk of malnutrition. Low arginine and nitric oxide bioavailability are implicated in morbidity related to sickle-cell disease. Simple interventions are required, especially in low-income settings. We aimed to test the hypotheses that: (1) supplementary arginine, citrulline, and daily chloroquine increase bioavailable arginine and flow-mediated dilatation (FMD; maximal diameter change; FMDmax %), a measure of nitric oxide-dependent endothelial function; and (2) protein energy supplementation in the form of ready-to-use supplementary food (RUSF) improves the height-for-age and body-mass index-for-age Z-scores in children with sickle-cell disease...
March 13, 2018: Lancet Haematology
https://www.readbyqxmd.com/read/29703336/disease-burden-complication-rates-and-health-care-costs-of-heparin-induced-thrombocytopenia-in-the-usa-a-population-based-study
#13
Binod Dhakal, Lisa Baumann Kreuziger, Lisa Rein, Ariel Kleman, Raphael Fraser, Richard H Aster, Parameswaran Hari, Anand Padmanabhan
BACKGROUND: Heparin-induced thrombocytopenia can be a life-threatening and limb-threatening complication of heparin therapy. Incidence and complication rates of this condition have been extrapolated from studies with modest sample sizes, and despite the availability of therapeutic interventions the outcomes of heparin-induced thrombocytopenia are not well understood. We aimed to estimate disease burden, complication rates, and costs of heparin-induced thrombocytopenia in the USA. METHODS: In this population-based study we analysed data from 2009 to 2013 from the Nationwide (National) Inpatient Sample (NIS), a large, all-payer inpatient health-care database in the USA...
May 2018: Lancet Haematology
https://www.readbyqxmd.com/read/29703335/chop-versus-gem-p-in-previously-untreated-patients-with-peripheral-t-cell-lymphoma-chemo-t-a-phase-2-multicentre-randomised-open-label-trial
#14
Mary Gleeson, Clare Peckitt, Ye Mong To, Laurice Edwards, Jacqueline Oates, Andrew Wotherspoon, Ayoma D Attygalle, Imene Zerizer, Bhupinder Sharma, Sue Chua, Ruwaida Begum, Ian Chau, Peter Johnson, Kirit M Ardeshna, Eliza A Hawkes, Marian P Macheta, Graham P Collins, John Radford, Adam Forbes, Alistair Hart, Silvia Montoto, Pamela McKay, Kim Benstead, Nicholas Morley, Nagesh Kalakonda, Yasmin Hasan, Deborah Turner, David Cunningham
BACKGROUND: Outcomes with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone) or CHOP-like chemotherapy in peripheral T-cell lymphoma are poor. We investigated whether the regimen of gemcitabine, cisplatin, and methylprednisolone (GEM-P) was superior to CHOP as front-line therapy in previously untreated patients. METHODS: We did a phase 2, parallel-group, multicentre, open-label randomised trial in 47 hospitals: 46 in the UK and one in Australia...
May 2018: Lancet Haematology
https://www.readbyqxmd.com/read/29703334/analysis-of-big-data-for-heparin-induced-thrombocytopenia-valuable-information-but-also-some-doubts
#15
Yves Gruel
No abstract text is available yet for this article.
May 2018: Lancet Haematology
https://www.readbyqxmd.com/read/29703333/optimising-initial-treatment-for-peripheral-t-cell-lymphoma-a-tough-nut-to-chop
#16
Ryan A Wilcox
No abstract text is available yet for this article.
May 2018: Lancet Haematology
https://www.readbyqxmd.com/read/29703332/sugar-video-games-and-vte-an-unseen-connection
#17
EDITORIAL
The Lancet Haematology
No abstract text is available yet for this article.
May 2018: Lancet Haematology
https://www.readbyqxmd.com/read/29602354/bittersweet-progress-for-haemophilia-a
#18
EDITORIAL
The Lancet Haematology
No abstract text is available yet for this article.
April 2018: Lancet Haematology
https://www.readbyqxmd.com/read/29550385/grb2-inhibition-a-new-potential-targeted-therapy-for-myeloid-malignancies
#19
Xavier Thomas, Etienne Paubelle
No abstract text is available yet for this article.
April 2018: Lancet Haematology
https://www.readbyqxmd.com/read/29550383/liposomal-grb2-antisense-oligodeoxynucleotide-bp1001-in-patients-with-refractory-or-relapsed-haematological-malignancies-a-single-centre-open-label-dose-escalation-phase-1-1b-trial
#20
Maro Ohanian, Ana Tari Ashizawa, Guillermo Garcia-Manero, Naveen Pemmaraju, Tapan Kadia, Elias Jabbour, Farhad Ravandi, Gautam Borthakur, Michael Andreeff, Marina Konopleva, Miranda Lim, Sherry Pierce, Susan O'Brien, Yesid Alvarado, Srdan Verstovsek, William Wierda, Hagop Kantarjian, Jorge Cortes
BACKGROUND: Activating mutations of tyrosine kinases are common in leukaemias. Oncogenic tyrosine kinases use the growth factor receptor-bound protein 2 (Grb2) for signal transduction, leading to activation of mitogen-activated protein kinase (MAPK) 1 and MAPK3 (ERK2 and ERK1). We hypothesised that inhibition of Grb2 would suppress ERK1 and ERK2 activation and inhibit leukaemia progression. To inhibit Grb2, a liposome-incorporated antisense oligodeoxynucleotide that blocks Grb2 protein expression, BP1001, was developed...
April 2018: Lancet Haematology
journal
journal
49595
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"